About Mastermind-like protein 2
Mastermind-like protein 2 (MAML2) is a protein
from Homo sapiens identified by UniProt accession
Q8IZL2, 1156 residues long.
MolForge cross-references it against 0 known binders and
204 disease associations.
Target properties
| Protein name | Mastermind-like protein 2 |
|---|
| UniProt accession | Q8IZL2 |
|---|
| Gene | MAML2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1156 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (204)
Diseases linked to this target (Open Targets).
- cancer · score 0.57
- neurodegenerative disease · score 0.53
- mean platelet volume · score 0.43
- hematocrit · score 0.42
- hemoglobin measurement · score 0.42
- ulcerative colitis · score 0.41
- total blood protein measurement · score 0.39
- pancreatic ductal adenocarcinoma · score 0.37
- pancreatic carcinoma · score 0.37
- lymphoid neoplasm · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8IZL2-F1 | alphafold | PREDICTED | 45.63 | — |
Amino-acid sequence (1156 residues)
MGDTAPPQAP AGGLGGASGA GLLGGGSVTP RVHSAIVERL RARIAVCRQH HLSCEGRYER GRAESSDRER ESTLQLLSLV QHGQGARKAG KHTKATATAA TTTAPPPPPA APPAASQAAA TAAPPPPPDY HHHHQQHLLN SSNNGGSGGI NGEQQPPAST PGDQRNSALI ALQGSLKRKQ VVNLSPANSK RPNGFVDNSF LDIKRIRVGE NLSAGQGGLQ INNGQSQIMS GTLPMSQAPL RKTNTLPSHT HSPGNGLFNM GLKEVKKEPG ETLSCSKHMD GQMTQENIFP NRYGDDPGEQ LMDPELQELF NELTNISVPP MSDLELENMI NATIKQDDPF NIDLGQQSQR STPRPSLPME KIVIKSEYSP GLTQGPSGSP QLRPPSAGPA FSMANSALST SSPIPSVPQS QAQPQTGSGA SRALPSWQEV SHAQQLKQIA ANRQQHARMQ QHQQQHQPTN WSALPSSAGP SPGPFGQEKI PSPSFGQQTF SPQSSPMPGV AGGSGQSKVM ANYMYKAGPS AQGGHLDVLM QQKPQDLSRS FINNPHPAME PRQGNTKPLF HFNSDQANQQ MPSVLPSQNK PSLLHYTQQQ QQQQQQQQQQ QQQQQQQQQQ QQQQQQQQQQ QSSISAQQQQ QQQSSISAQQ QQQQQQQQQQ QQQQQQQQQQ QQQQQPSSQP AQSLPSQPLL RSPLPLQQKL LLQQMQNQPI AGMGYQVSQQ QRQDQHSVVG QNTGPSPSPN PCSNPNTGSG YMNSQQSLLN QQLMGKKQTL QRQIMEQKQQ LLLQQQMLAD AEKIAPQDQI NRHLSRPPPD YKDQRRNVGN MQPTAQYSGG SSTISLNSNQ ALANPVSTHT ILTPNSSLLS TSHGTRMPSL STAVQNMGMY GNLPCNQPNT YSVTSGMNQL TQQRNPKQLL ANQNNPMMPR PPTLGPSNNN NVATFGAGSV GNSQQLRPNL THSMASMPPQ RTSNVMITSN TTAPNWASQE GTSKQQEALT SAGVRFPTGT PAAYTPNQSL QQAVGSQQFS QRAVAPPNQL TPAVQMRPMN QMSQTLNGQT MGPLRGLNLR PNQLSTQILP NLNQSGTGLN QSRTGINQPP SLTPSNFPSP NQSSRAFQGT DHSSDLAFDF LSQQNDNMGP ALNSDADFID SLLKTEPGND DWMKDINLDE ILGNNS
Explore Mastermind-like protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets